Uveal melanomas comprise 5% of melanomas in the US^[@R1]^. They derive from melanocytes in the choroid, iris, or ciliary body of the eye and constitute the most common eye cancer. Ten-year mortality is 50%, markedly higher than most other melanoma subtypes^[@R2],[@R3]^, and there currently are no effective treatment options for patients with metastatic disease^[@R4]--[@R6]^. An improved understanding of how uveal melanoma progresses from primary to metastatic disease promises to identify crucial pathogenic steps that could inform the development of new modalities of treatment and prognostication.

Several large-scale sequencing efforts have catalogued the genomic landscape of primary uveal melanoma^[@R7]--[@R10]^ and revealed a suite of genetic alterations distinctive from other melanoma subtypes^[@R11]^. Uveal melanomas commonly harbor mutations that activate the G-protein alpha-q signaling cascade, affecting *GNAQ*^[@R12]^, *GNA11*^[@R13]^, *PLCB4*^[@R14]^, or *CYSLTR2*^[@R15]^ that, with rare exceptions, occur in a mutually exclusive pattern. They additionally have secondary somatic alterations affecting *BAP1*^[@R10],[@R16]^, *SF3B1*^[@R8]^, or *EIF1AX*^[@R9]^ that tend to also to occur exclusive of each other. Further, uveal melanomas have recurrent copy number alterations involving gains of chromosomes 6p and 8q as well as losses of chromosomes 1p, 3, 6q, 8p, and 16q. *BAP1* constitutes the major tumor suppressor gene on chromosome 3, and *MYC* is possibly the oncogene on chromosomal arm 8q. It is unclear which genes drive the other copy number changes.

In contrast to primary uveal melanoma, few uveal melanoma metastases have been sequenced to date^[@R17]^- particularly lacking are studies of primary tumors and patient-matched metastases. Uveal melanomas have a propensity to metastasize via hematogenous routes to the liver, a distant site with respect to their origins in the eye. There is a latency between removal of the primary tumor and the emergence of metastases that ranges from months to decades^[@R4],[@R18]^. In order to better understand the evolution of metastatic uveal melanoma, we performed multi-region DNA sequencing of primary uveal melanomas and patient-matched metastases.

Results {#S1}
=======

We sequenced non-lesional reference tissue, one or more regions of the primary tumor, and corresponding liver metastases from 35 patients with metastatic uveal melanoma ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}). The majority of tissues were microdissected from archival paraffin blocks. Sequencing libraries from formalin-fixed paraffin-embedded (FFPE) tissues have lower complexity^[@R19]^, and we therefore elected to perform targeted sequencing of a panel of 500 genes commonly involved in cancer ([Supplementary Table 2](#SD4){ref-type="supplementary-material"}), allowing us to sequence a smaller genomic footprint at substantially higher coverage. On average, each sample was sequenced to 423-fold unique coverage, enabling sensitive mutation detection and helping to overcome the well-documented^[@R20]^ challenge of detecting certain *BAP1* mutations.

A workflow to delineate the evolution of metastatic uveal melanoma. {#S2}
-------------------------------------------------------------------

Our workflow to deduce the genetic evolution of metastatic uveal melanoma is illustrated by the example case (A11) shown in [Figure 1](#F1){ref-type="fig"}. From this patient, we microdissected two histologically distinct areas of the primary melanoma and part of the optic nerve, which served as a source of non-lesional reference tissue ([Fig. 1a](#F1){ref-type="fig"}). Metastatic tissue was obtained from the patient's liver core biopsy ([Fig. 1a](#F1){ref-type="fig"}).

Only two somatic point mutations were identified, reflecting the low mutation burden that is typical of this melanoma subtype. Both mutations, a heterozygous, gain-of-function *GNA11* variant and a hemizygous, loss-of-function *BAP1* variant, were shared between all three melanoma samples ([Fig. 1b](#F1){ref-type="fig"}). To determine the allelic status of mutations, we bioinformatically estimated the fraction of neoplastic cells in each melanoma region. The blue lines in [Figure 1b](#F1){ref-type="fig"} denote the expected mutant allele fractions where a heterozygous mutation would be expected to reside with fading zones that indicate the 95% confidence intervals. The loss of heterozygosity of the *BAP1* mutation is evident by its mutant allele fraction falling outside those zones in all three samples.

We next inferred copy number alterations using the software package CNVkit^[@R21]^ ([Fig. 1c](#F1){ref-type="fig"}). In the example case, some copy number alterations were shared between all samples, including a deletion of chromosome 3 that encompassed the *BAP1* gene and thus explains how the *BAP1* mutation became hemizygous. A loss of chromosomal arm 9p and a gain of chromosomal arm 8q were also present in each melanoma region ([Fig. 1c](#F1){ref-type="fig"}).

By contrast, some copy number alterations were exclusive to certain tissues. For instance, there was a superimposed homozygous deletion encompassing the *CDKN2A* gene that was only present in the unpigmented area of the primary melanoma (Mel1) and the metastasis ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Also, the amplitudes of 8q gain differed among the melanoma tissues ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}) - the pigmented area of the primary (Mel2) had 5 absolute copies, while the unpigmented area (Mel1) had 9 absolute copies, and the metastasis had 11 absolute copies. These observations indicate stepwise deletion of *CDKN2A* paralleled by stepwise amplification of 8q during the evolution of this case.

The distribution of somatic mutations and copy number changes among the three tumor areas made it possible to delineate the sequential order in which they arose during tumor evolution. All three tumor samples shared the *GNA11*^*Q209L*^ mutation, bi-allelic *BAP1* alterations, mono-allelic deletion of *CDKN2A*, and gain of at least three copies of chromosomal arm 8q -- this indicates that these alterations arose comparatively early and thus reside on the trunk of the evolutionary tree ([Fig. 1d](#F1){ref-type="fig"}). The Mel1 area of the primary tumor and the metastasis shared a homozygous deletion of *CDKN2A* and additional levels of 8q gain, placing these somatic alterations on a shared branch of the evolutionary tree ([Fig. 1d](#F1){ref-type="fig"}). Finally, the metastasis harbored the highest amplitude of 8q gain, placing these extra levels of 8q gain on the terminal branch of the evolutionary tree ([Fig. 1d](#F1){ref-type="fig"}).

In aggregate, activation of *GNA11*, bi-allelic loss of *BAP1*, low-level gain of 8q, and mono-allelic loss of *CDKN2A* occurred in the most recent common ancestral clone. A subclone with higher levels of 8q gain and bi-allelic loss of *CDKN2A* emerged in the primary (Mel1), and this clone gave rise to a liver metastasis with even higher levels of 8q gain ([Fig. 1d](#F1){ref-type="fig"}). The equivalent detailed evolution of the remaining 34 cases is available in the supplementary dataset on FigShare (<https://doi.org/10.6084/m9.figshare.6845675.v1>).

The genomic landscapes of primary and metastatic uveal melanoma. {#S3}
----------------------------------------------------------------

We next annotated the driver mutations in each sequenced region from all 35 patients' tumors. As expected, based on prior studies, we observed mutually exclusive mutations involving genes in the Gαq signaling cascade as well as alterations affecting *BAP1*, *SF3B1*, and *EIF1AX* that tended to not overlap. However, in contrast to prior studies, we found a long tail of additional mutations ([Fig. 2](#F2){ref-type="fig"}) that included loss-of-function mutations affecting *CDKN2A*, *PBRM1*, *PIK3R2*, and *PTEN*, loss-of-heterozygosity over the *GNAQ* locus, and gain-of-function mutations affecting *EZH2*, *PIK3CA*, and *MED12*. The majority of these alterations were in just one region of the primary tumor or private to their metastases (designated in [Figure 2](#F2){ref-type="fig"} by the faded tiles), indicating that they arose later during progression, after mutational activation of Gαq and mutations of *BAP1*, *SF3B1*, and *EIF1AX*. These mutations are thus considered tertiary driver mutations, likely explaining why they were not apparent in prior bulk sequencing of primary uveal melanomas.

Early mutational activation of the Gαq signaling pathway is pathognomonic of uveal melanoma. {#S4}
--------------------------------------------------------------------------------------------

Activation of Gαq signaling was ubiquitous with mutations affecting *GNA11*, *GNAQ*, *CYSTLR2*, or *PLCB4* in a mutually exclusive pattern in all 35 cases in our cohort, consistent with prior findings. The mutations activating the Gαq signaling pathway were always shared among all samples from a given patient, indicating that they undergo selection early and are required for tumor formation ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). This is also consistent with the recent finding that these mutations are common in choroidal nevi, which is likely a precursor for a subset of uveal melanomas^[@R22]^. Gαq-signaling-pathway mutations were heterozygous in the majority of cases. However, in six cases, *GNAQ* mutations were hemizygous or homozygous ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}) as a consequence of additional genetic alterations that eliminated the wild-type allele. Loss-of-heterozygosity of mutant *GNAQ* tended to take place later during progression ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). Preferential expression of mutant over wild-type *GNAQ* has been observed previously^[@R23]^, and our data offer a mechanism as to how this can occur.

Uveal melanomas with *SF3B1* or *EIF1AX* mutations acquire additional oncogenic mutations during metastatic progression. {#S5}
------------------------------------------------------------------------------------------------------------------------

We next sought to investigate the relative timing of *BAP1*, *SF3B1*, and *EIF1AX* mutations. Patients whose uveal melanomas have *SF3B1* or *EIF1AX* mutations tend to have a better prognosis than those with *BAP1* mutations^[@R7]^. Likely because our cohort consisted entirely of metastatic uveal melanomas, *SF3B1*- and *EIF1AX*- mutant cases were underrepresented (*n* = 7). In general, the *BAP1*, *SF3B1*, and *EIF1AX* mutations did not co-occur. However, one *EIF1AX*-mutant tumor also had bi-allelic *BAP1* mutations ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). This case was further unusual because the *EIF1AX* mutation resided at codon 70, a site that is recurrently mutated but less frequently affected than the N-terminal region of *EIF1AX*. Finally, the Gq-pathway mutation in this atypical case involved *CYSTLR2*, which is rare compared to *GNAQ* and *GNA11* mutations.

The cases with *SF3B1* or *EIF1AX* mutations tended to have additional oncogenic alterations. Two had homozygous *CDKN2A* deletions, three had PI3-kinase pathway mutations (*PTEN*^*C218\**^, *PIK3CA*^*H1047R*^, and *PIK3R2*^*N485S*^), and one had a *MED12* hotspot mutation ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). In one *EIF1AX*-mutant case, we sequenced two areas of primary tumor, and the more histologically advanced area acquired a deletion of chromosome 3 ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}) -- this was notable because it has been proposed that primary tumors without monosomy 3 may progress towards a more malignant stage by losing chromosome 3^[@R24]^.

The *SF3B1* and *EIF1AX* mutations were predominately truncal, whereas the additional oncogenic mutations were more often branchial. This pattern suggests that *SF3B1* and *EIF1AX* mutations undergo selection early but may require additional oncogenic alterations to complement their likely limited ability to drive disease progression and metastatic dissemination.

Selection to disrupt chromatin remodeling factors begins early and continues throughout the evolution of metastatic uveal melanoma.

*BAP1* mutations were expectedly common in our cohort of uveal melanomas that became metastatic and were usually shared among all samples from a given patient, placing them on the trunks of evolutionary trees ([Fig. 3a](#F3){ref-type="fig"}). These observations suggest that bi-allelic *BAP1* mutations tend to precede metastatic dissemination.

There were, however, two cases in which *BAP1* alterations had a different distribution between primary tumors and their metastases ([Fig. 3b](#F3){ref-type="fig"},[c](#F3){ref-type="fig"}). In case A29, the primary tumor had a frameshift mutation and a deletion affecting *BAP1*, but its metastasis had only very few reads of the frameshift mutation and did not have a deletion on chromosome 3 ([Fig. 3b](#F3){ref-type="fig"}). In case A13 ([Fig. 3c](#F3){ref-type="fig"}), the primary tumor and the metastasis shared a point mutation in *BAP1*, but only the primary had eliminated the second allele of *BAP1*, whereas the mutation in the metastasis remained heterozygous. The metastases from cases A29 and A13 were both negative for BAP1 protein by immunohistochemistry ([Fig. 3d](#F3){ref-type="fig"}), suggesting that either *BAP1* was silenced epigenetically, or the mutation escaped detection by our methods. Overall, these two cases raise the possibility that bi-allelic loss of *BAP1* is not absolutely required for metastatic dissemination. This would be consistent with anecdotal reports of monosomy 3 occurring later in the evolution of uveal melanoma^[@R25],[@R26]^; however, further studies will be necessary to confirm whether this is true.

We also observed mutations in other chromatin remodeling factors, including hemizygous, loss-of-function mutations in *PBRM1* and gain-of-function *EZH2* mutations ([Fig. 3e](#F3){ref-type="fig"}). *PBRM1* encodes a critical subunit of the SWI/SNF chromatin remodeling complex, and *EZH2* encodes the enzymatic subunit of Polycomb repressive complex 2 (PRC2)^[@R27]^. BAP1 is a negative regulator of PRC1 which activates PRC2, so *BAP1* loss is thought to promote PRC2 activation. The SWI/SNF chromatin remodeling complex also opposes PRC2 activity in maintaining cell-state appropriate chromatin modifications^[@R28]--[@R30]^; therefore, the alterations in *PBRM1* and *EZH2* likely shift the balance of chromatin remodeling activity further towards PRC2 dominance. In contrast to *BAP1* mutations, which occurred earlier in most cases, mutations affecting *PBRM1* or *EZH2* occurred later, as they were generally not shared among all tumor areas of a given patient.

Copy number gains of chromosome 8q arise in the primary tumor and ramp up during metastatic progression.

Copy number gains of chromosome 8q were present in nearly every case and were typically shared among the different tumor areas of a given patient ([Fig. 4a](#F4){ref-type="fig"}), suggesting that they occur early during evolution of the primary tumor, prior to metastatic dissemination, as previous data have suggested^[@R31]^. There were three exceptions to this pattern in which copy number gains were not shared in every tumor area ([Fig. 4b](#F4){ref-type="fig"}), indicating that it is at least possible for metastatic dissemination to precede 8q gain.

We delved deeper into the amplitudes of 8q gain and observed that the copy number of 8q tended to increase from primaries to metastases. For instance, as described in case A11, one region of the primary tumor had 5 copies of 8q, while another region of the primary tumor had 9 copies, and the metastasis had 11 copies ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). In other examples, the primary tumor for case A61 had 4 copies of 8q, and the metastasis had 11 copies ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}), and in case A06, the primary tumor had 4 copies of chromosomal arm 8q, while the metastasis had 9 copies ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). Overall, metastases had more copies of 8q than their corresponding primary tumors in most patients, with an average of 6 versus 4 copies (*P* = 0.002 two-tailed t-test) ([Fig. 4c](#F4){ref-type="fig"}). We validated our sequencing-based copy number estimates by measuring allelic imbalance and assessing copy number with independent technologies, including multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}--[e](#SD1){ref-type="supplementary-material"}). The findings of these methods were concurrent and indicate progressive increase of 8q copy number during progression to metastatic disease.

The sequential order of genetic alterations during metastatic progression. {#S6}
--------------------------------------------------------------------------

We deduced the sequential order in which somatic alterations undergo selection during the evolution of metastatic uveal melanoma by calculating how often a given alteration resided on the trunk versus the branch of each evolutionary tree ([Fig. 5a](#F5){ref-type="fig"}). This analysis confirmed that Gαq-pathway mutations are the earliest mutations to undergo selection, followed by gain of chromosomal arm 8q as well as *BAP1*, *SF3B1*, or *EIF1AX* mutations. Selective pressures continue to operate on these pathways at comparatively later points in the progression cascade by way of *GNAQ* loss-of-heterozygosity, additional chromatin remodeling mutations, and further ramp-up of 8q copy number ([Fig. 5a](#F5){ref-type="fig"}). Copy number alterations affecting chromosomal arms 16q, 8p, 1p, 6p, and 6q underwent selection at intermediate points in the evolutionary cascade ([Fig. 5a](#F5){ref-type="fig"}).

Finally, we compared the frequency of somatic alterations between primaries and metastases. Most somatic alterations were somewhat enriched in metastases, but only copy number changes of 6q, 1q, and high-level gains of 8q (copy number increase by at least 3 copies) reached statistical significance ([Fig. 5b](#F5){ref-type="fig"}). In particular, gains of 1q were frequent in our cohort compared to prior studies on primary uveal melanomas, consistent with their emergence later during progression ([Fig. 5](#F5){ref-type="fig"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Further studies will be needed to elucidate the gene(s) driving the selection of these aberrations.

Correlations with clinical outcomes. {#S7}
------------------------------------

Genomic studies of primary uveal melanomas have revealed several mutations with prognostic value^[@R8]--[@R10]^. Our cohort was underpowered to discover new biomarkers of this type, but capitalizing on a unique aspect of our study, we instead investigated whether specific evolutionary routes of progression correlated with clinical outcomes.

As all of our patients ultimately developed metastatic disease, we assessed correlations between clinical outcomes (disease-free survival, survival after metastasis, and overall survival) and features of their genetic evolution (i.e. metrics of the phylogenetic trees, such as individual and combined lengths of trunk and branches as well as branch separation; see [Methods](#S9){ref-type="sec"}) ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"},[b](#SD1){ref-type="supplementary-material"}). The overarching goal was to investigate whether certain evolutionary trajectories were associated with clinical outcomes, as was recently shown to be true in renal cell carcinoma^[@R32]^.

Patients whose trees had longer metastasis branches and shorter primary branches tended to have better disease-free survival ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}) -- this comparison was statistically significant by itself (R = 0.34, *P* = 0.046), though it did not remain significant after correcting for multiple-hypothesis testing. If this finding is validated in larger cohorts, it likely reflects the fact that some uveal melanomas require more genetic alterations to develop clinically detectable metastases, and these uveal melanomas have better survival metrics reflecting the time required to incrementally acquire the necessary set of alterations.

Discussion {#S8}
==========

Our study shows that uveal melanomas continue to genetically evolve as they progress from primary to metastatic disease, as indicated by the fact that metastases tend to have more oncogenic mutations than primary tumors. This contrasts with most other tumor types for which metastases are genetically similar to primary tumors^[@R33],[@R34]^. One peculiar aspect of uveal melanoma is that in many cases metastases develop after a long period of latency after successful eradication of the primary tumor -- this latency period may partially reflect the additional time needed to acquire the necessary mutations for growth at the distant site ([Fig. 6](#F6){ref-type="fig"}). In addition to having more oncogenic alterations, metastases also acquire distinct oncogenic alterations, including additional copies of chromosomes 1q and 8q. This may reflect different selective pressures operating in the liver, the major organ in which metastases develop in uveal melanoma.

Prior sequencing studies of uveal melanoma mostly analyzed a single tissue sample from the primary tumor. Our multi-region sequencing of primaries and metastases revealed multiple novel mutations, expanding the catalog of driver mutations for this aggressive melanoma subtype. These novel mutations were more common in uveal melanomas with *SF3B1* or *EIF1AX* mutations, and they possibly complement the otherwise limited ability of *SF3B1* and *EIF1AX* mutations to drive metastatic disease. The earliest driver mutations in primary uveal melanoma are not easily druggable, but there is hope that some of the newly recognized mutations found in some metastases can be targeted therapeutically.

We also observed loss-of-heterozygosity of mutant *GNAQ*, but not *GNA11*, in multiple samples, indicating hidden complexity in oncogenic signaling through mutant Gαq subunits. The Q209 alterations in GNAQ and GNA11 abrogate their GTPase activity, similar to mutant RAS. RAS mutations also undergo loss-of-heterozygosity by a variety of mechanisms that shift the allelic balance towards the mutant allele^[@R35]^. Earlier studies using Sanger sequencing have reported increased frequency of *GNA11* mutations in metastatic uveal melanomas, whereas *GNAQ* mutations are more common in benign lesions, such as blue nevi^[@R13]^. This led to the proposition that *GNA11* mutations are more potent. The finding of recurrent loss-of-heterozygosity of *GNAQ* mutations later in progression may indicate that *GNAQ*, but not *GNA11*, requires a second hit to fully activate the pathway, which could explain the association with *GNA11* mutations with more aggressive disease.

Uveal melanomas have been proposed to arise after an early, punctuated burst of mutations followed by a period of neutral evolution^[@R20]^. In our cohort, we found three cases in which metastatic dissemination preceded 8q gain and potentially two cases in which metastatic dissemination preceded bi-allelic loss of *BAP1*. These cases suggest that it is at least possible for metastatic dissemination to occur before the neoplasm has developed the full complement of oncogenic mutations ([Fig. 6](#F6){ref-type="fig"}), though additional studies, focused on the earlier stages of neoplasia, will be needed to fully resolve the incipient events involved in the evolution of uveal melanoma. We also found multiple added driver mutations in the branches of phylogenetic trees, arguing against neutral evolution in the latter phases of evolution.

In summary, our study reveals the selective pressures operating on primary tumors and metastases during the evolution of uveal melanoma and offers candidate biomarkers for staging and prognosis.

Online Methods {#S9}
==============

Patient samples. {#S10}
----------------

Primary and patient-matched metastatic uveal melanoma tissues were from the Ocular Tumor Division in the Copenhagen University Hospital. Most primary uveal melanomas were from archival (formalin-fixed paraffin-embedded) blocks of enucleated eyes, though some were derived from fresh biopsies, as indicated ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}). All metastases were liver metastases. Among the metastatic tissues, most were derived from archival blocks of liver core biopsies with a subset derived from archival blocks of liver resections, as indicated ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}). All metastases were treatment naïve. Most reference (normal) tissues were microdissected from non-lesional areas of the primary tumor blocks with some originating from patient-matched blood, as indicated ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}).

This retrospective study was approved by the regional ethical committee in Copenhagen, Denmark (H-2-2013-064) and the Danish Data Protection agency (RH-2015--167). All tissues were collected in accordance with the institutional review board with regard to informed consent.

The overarching design of this study is also described in the **Life Sciences Reporting Summary**.

Microdissection and DNA extraction. {#S11}
-----------------------------------

All microdissections were performed with a scalpel under a dissection scope and guided by a pathologist with the intent to maximize tumor cell content. 10-μm unstained sections (between 4--10 levels) were used. Genomic DNA was isolated with Qiagen DNA FFPE Tissue Kit (p/n 56404). When possible, we microdissected multiple regions of the primary tumor. In total, we collected and sequenced 53 pieces of primary uveal melanoma, 36 pieces of uveal melanoma metastasis, and 35 normal (i.e. non-lesional) tissues.

DNA sequencing and analysis. {#S12}
----------------------------

25--250 ng of genomic DNA was sheared (250 bp target fragment size) and prepared for Illumina sequencing as previously described^[@R36],[@R37]^. As expected, the smaller FFPE-derived neoplasms had lower library complexities. We therefore elected to perform targeted sequencing of a panel of 538 genes commonly involved in cancer (see [Supplementary Table 2](#SD4){ref-type="supplementary-material"} for baits), favoring more samples and more coverage over a larger sequencing footprint. This decision did not hinder the overarching goal of the study, which was to delineate the order in which known driver mutations arise during the evolution of metastatic uveal melanoma. On average, each sample was sequenced to 423-fold de-duplicated coverage (see [Supplementary Table 1](#SD3){ref-type="supplementary-material"} for more details). Baits were developed with the customized Nimblegen SeqCap EZdeveloper platform. Sequencing was performed on an Illumina HiSeq 2500 instrument.

Alignment, grooming, and mutation calling were performed with the following software packages: Burrows-Wheeler Aligner (BWA), Genome Analysis Tool-Kit (GATK), Picard, and MuTect. Sequencing metrics for each sample are available in [Supplementary Table 1](#SD3){ref-type="supplementary-material"}.

CNVkit was used to infer copy number information. This software can be run in reference or reference-free mode. We elected to run CNVkit in reference mode, as this consistently produces higher quality copy number calls when references (i.e. normal tissues) are available. Two separate reference pools were generated for this study -- non-neoplastic eye tissue and non-neoplastic liver tissue. The eye reference was used to infer copy number information from primary tumors whereas liver reference tissue was used to infer copy number information from metastases.

Driver gene calling. {#S13}
--------------------

The driver genes in each case are summarized in [Figure 2](#F2){ref-type="fig"}. We include any mutation affecting *GNAQ*, *GNA11*, *PLCB4*, *CYSTLR2*, *BAP1*, *EIF1AX*, or *SF3B1* -- this is based on these genes' previously described roles in driving uveal melanoma. We also include alterations affecting *CDKN2A*, *PBRM1*, and *EZH2* due to their recurrence in our study and known roles as cancer genes in other tumor types. Moreover, we include hotspot mutations affecting *PIK3CA* and *MED12*, which were observed once in our study but are common in pan-tumor analyses. Finally, we include inactivating mutations affecting *PTEN* and *PIK3R2*, which are prominent tumor suppressors in other cancers and are lost in a bi-allelic fashion in our study.

Copy number estimation. {#S14}
-----------------------

To deduce the discrete levels for each copy number alteration, we first calculated the expected log ratios for each level of gain or loss. For example, a mono-allelic deletion should have a log~2~(tumor/reference) segmentation value of −1 (because log~2~(1/2) = −1); however, in practice, this is never observed because each tumor has some level of stromal cell contamination, and stromal cells do not harbor copy number alterations. We took into account stromal cell contamination for each sample by proportionally weighting the expected segment value for a given copy number alteration with the expected log~2~(stroma/reference) from stromal cells (assumed to be 0) in that sample.

Supplementary dataset covering the evolution of all 35 cases. {#S15}
-------------------------------------------------------------

In [Figure 1](#F1){ref-type="fig"}, we present the detailed evolution of an example case, including the distribution of point mutations, copy number alterations, and allelic imbalances over each tumor region from a single patient. We analyzed all 35 cases in this cohort to the same level of detail, and we include the detailed evolution of the other 34 cases in the following supplementary dataset^[@R38]^ hosted at Figshare (<https://doi.org/10.6084/m9.figshare.6845675.v1>).

Phylogenetic tree construction. {#S16}
-------------------------------

Point mutation calls are available in [Supplementary Table 3](#SD5){ref-type="supplementary-material"}, and copy number calls are available in [Supplementary Table 4](#SD6){ref-type="supplementary-material"}. Phylogenetic trees were constructed as described for [Figure 1](#F1){ref-type="fig"} from the shared and private somatic alterations. All phylogenetic trees are rooted to the germline state. The trunk and branch lengths for each phylogenetic tree are provided in [Supplementary Table 1](#SD3){ref-type="supplementary-material"}. When multiple mutations occurred on the same segment of the phylogenetic tree, they are bracketed, serving as an indication that it is not possible to deduce the relative order in which they occurred.

Tumor cellularity inference.

Most tumors are infiltrated with stromal cells, resulting in a mixture of sequencing reads derived from stromal and tumor cells. It is important to accurately measure tumor cell content in order to ensure that sequencing depth is sufficiently powered to detect mutations and also to measure the zygosity of somatic mutations. We employed a series of bioinformatic approaches to estimate tumor cell content^[@R36],[@R39]^. Specifically, copy number alterations induce allelic imbalances over germline heterozygous SNPs, and we used the extent of allelic imbalance to measure tumor cellularity. We also calculated tumor cell content based on somatic mutation allele fractions after taking into account the copy number status of the locus. When possible, tumor cell content was calculated from both germline and somatic variant allele fractions to produce a consensus estimate (see [Supplementary Table 1](#SD3){ref-type="supplementary-material"}).

8q copy number inference. {#S17}
-------------------------

In [Supplementary Figure 4a](#SD1){ref-type="supplementary-material"},[b](#SD1){ref-type="supplementary-material"}, we inferred discrete levels of copy number gain over chromosomal arm 8q as described in the "Copy number estimation" section above. We validated these estimates several ways.

In [Supplementary Figure 4c](#SD1){ref-type="supplementary-material"}, we calculated the ratio of reads mapping to the major versus minor allele over heterozygous SNPs situated on chromosomal arm 8q. Here, the term "major allele" refers to the more abundant, or amplified, allele in the tumor. To calculate this ratio, we first subtracted out the reads emanating from stromal cells -- these reads would have allelic ratios of 1:1, thereby diluting the overall ratio. The specific formula to determine the ratio of reads in the tumors cells that we used was as follows: $$\text{N} = \text{~Ratio~of~the~major~to~minor~allele~in~tumor~cells}$$ $$\text{S} = \text{~Overall~major~allele~read~fraction}$$ $$\text{X} = \text{~Fraction~of~tumor~cells}$$ $$\text{N} = \left( {2^{*}\text{S} - 1} \right)/\left( {\text{X} - \text{X}^{*}\text{S}} \right)$$ For higher level gains, there are several potential allelic combinations (see [Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"} for a schematic); we therefore show the expected relationship between absolute copy number and major to minor allele ratios after considering all of these possibilities ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}, left panel). We next plotted the observed relationship between absolute copy number and major to minor allele ratios from our data ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}, right panel). Note that the observed relationship closely mirrors the expected relationship. In particular, tumors with high levels of 8q gain were more likely to have greater ratios of major to minor allelic reads. In aggregate, the allelic ratios over chromosomal arm 8q support our absolute copy number inferences.

In [Supplementary Figure 4d](#SD1){ref-type="supplementary-material"}, we used multiplex ligation-dependent probe amplification (MLPA)^[@R40]^ to measure 8q levels in 8 primary tumors predicted to harbor between 2--6 copies of chromosomal arm 8q. DNA was extracted using the QIAamp DNA Micro Kit (Qiagen), followed by standard sodium acetate/ethanol precipitation for optimal purity. Probes were ligated to specific DNA sequences on chromosomes 1, 3, 6 and 8 using the SALSA MLPA KIT P027-B1 Uveal Melanoma (MRC-Holland). In addition, 12 reference probes were ligated to chromosomes 2, 4, 5, 10, 11, 12 13, 14, 15 and 18. The signal intensities of the various probes were measured using capillary electrophoresis on a Genetic Analyzer 3130xl (Applied Biosystems). The signal intensity of each probe was normalized to the signal intensity of each reference probe and the relative amount of each target sequence was calculated using the Coffalyzer. Net data analysis software from MRC Holland. The *y*-axis of [Supplementary Figure 4d](#SD1){ref-type="supplementary-material"} depicts the ratio of 8q signal to other parts of the genome without copy number alterations. It is important to note that MLPA signals are subject to saturation at higher level gains, providing a relative (rather than an absolute) estimate of copy number. We observed a near perfect correlation (R = 0.97) between MLPA ratios and absolute copy number estimates from sequencing data, supporting our absolute copy number inferences.

In [Supplementary Figure 4e](#SD1){ref-type="supplementary-material"}, we performed fluorescence in situ hybridization (FISH) to validate copy number of chromosomal arm 8q. In the right panel, FISH was performed using probes targeting c-MYC (Vysis LSI MYC spectrum orange probe) and CEP12 (Vysis CEP12 spectrum green probe) (both probes from Abbott Molecular Inc). Slides were scanned with a fluorescence microscope (Carl Zeiss AxioImager.Z2) and analyzed using the Metafer4 v 3.8.12 software (Metasystems) per manufacturer's instructions. Tumor-bearing areas were identified by a pathologist using the DAPI filter at low magnification (10× lens) with the aid of the H&E. All areas involving tumor cells were scanned and within this area cells, which did not overlap and had bright signals for the probes were used for enumeration. Nuclei that had complete absence of signals for the control probe (CEP12) were excluded. At least 30 cells were analyzed per case. In the left panel, the tumor specimens were placed in a culture medium immediately after surgery and analyzed. The following fluorescent probes were hybridized to the tissues: Telomeric probe for chromosome 1p (Vysis TelVysion 1p) and centromeric probes for chromosome 3 (CEP3 D3Z1), 6 (CEP6 D6Z1), and 8 (CEP8) (all probes from Abbott Molecular, Inc.; [www.abbottmolecular.com](http://www.abbottmolecular.com/)). The probes were visualized and counted using a fluorescence microscope. At least 100 cells were evaluated by two technicians and copy number variations in more than 10% of the cells were used as a cut off. The six tumors analyzed with a centromeric 8 probe were chosen because they did not have copy number transitions across the centromere of chromosome 8. The copy number estimates from our sequencing data typically aligned with the mode counts from the FISH data ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}).

Statistics. {#S18}
-----------

In [Figure 1b](#F1){ref-type="fig"}, we calculated the fraction of tumor cells in each microdissected tissue (described above) -- the blue lines are anchored at half of that value (i.e. the expected mutant allele fraction of a fully clonal, heterozygous somatic mutation). The fading zones represent the 95% confident intervals. This was calculated under the assumption that mutant reads are sampled randomly from the total pool of mutant alleles in our DNA input, and therefore the final mutant allele fraction should fall within a binomial distribution around the expected mutant allele fraction of a fully clonal, heterozygous somatic mutation. Under this assumption the standard deviation of this distribution is dependent upon the sequencing depth (SD) in that sample and tumor cellularity (TC) as follows: ((0.5\*TC) -- (0.5\*TC)^2^) × SD)^0.5^. The 95% confidence interval was calculated by multiplying the standard deviation by 1.96. Finally, these confidence intervals were converted to fractions by dividing them by the total sequencing depth in that sample.

In [Figure 4c](#F4){ref-type="fig"}, we performed a two-tailed *t*-test, assuming equal variance, to compare the level of copy number gain of chromosomal arm 8q in primary tumors (*n* = 53) versus metastases (*n* = 36) (degrees of freedom = 87).

In [Figure 5b](#F5){ref-type="fig"}, for the genomic alterations shown in [Figure 5](#F5){ref-type="fig"}, we tabulated the number of times each occurred in metastases and primaries. We tested the probability that genomic alterations were enriched in metastases or primaries against the null hypothesis that the alterations should be equally distributed in each compartment. The *P*-values shown in [Figure 5](#F5){ref-type="fig"} reflect two-tailed probabilities under the assumption that our sampling of genomic alterations fits a binomial distribution of enrichments dictated by sampling size. Adjustments for multiple-hypothesis testing were not performed.

In [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}, we sought to identify significant associations between clinical outcomes and phylogenetic-tree features. We took several measurements of phylogenetic trees from each case (see [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}), including tree height, trunk length, branch lengths, and branch separation. Next, we investigated whether any of these measurements correlated with disease-free survival, survival after metastasis, or overall survival. In total, we made 18 pairwise comparisons between the 6 phylogenetic-tree measurements and the 3 clinical outcome datatypes. Each comparison comprised 35 data points, corresponding to each patient in the study. The correlations are shown as R-values (Pearson correlation coefficients) in [Supplementary Figure 6b](#SD1){ref-type="supplementary-material"}. We also performed a linear regression analysis to produce *P*-values for each correlation against the null hypothesis that the correlation coefficient (R-value) should be 0. Lastly, we report adjusted *P*-values, which were corrected for multiple-hypothesis testing using the Bonferroni correction.

Data availability. {#S19}
------------------

The raw sequencing data are available at the European Genome Phenome Archive under accession EGAD00001004453.
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![The patterns of somatic alterations within a patient's tumor areas provide insights in the sequential order in which they arose (example case A11)\
**a,** H&E sections of the enucleation specimen show morphologically distinct areas. The metastatic tissue stemmed from a liver core biopsy of the patient. Dotted regions were microdissected for genomic analyses. **b,** Point mutations are stratified by their mutant allele fractions (MAFs) in the two regions of the primary tumor and the metastasis. The blue bars indicate the expected MAFs of fully-clonal, heterozygous mutations after accounting for stromal cell contamination, with shadings indicating confidence intervals where those mutations should reside. Note the presence of a *GNA11*^*Q209L*^ mutation that is fully clonal and heterozygous in all samples. By contrast, the *BAP1*^*Y173C*^ mutation has an elevated MAF, indicating that it underwent loss-of-heterozygosity. **c,** Heatmap displaying copy number increases (red) or decreases (blue) for each sample (rows) across the genome with chromosomal boundaries indicated. Additional details related to deletion of *CDKN2A* and gain of chromosomal arm 8q are shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. **d,** Inferred evolution of case A11 with mutations shared among all samples forming the trunk, and mutations not present in all samples forming the branches. The length of the trunk and branches is scaled by the total number of mutations in the samples.](nihms-1529305-f0001){#F1}

![The spectrum of driver mutations in uveal melanoma.\
Multi-region sequencing of primary and matched metastases was performed on tumors from 35 patients. The spectrum of driver mutations (rows) in all patients (columns) is shown. Gain/change-of-function and loss-of-function mutations are respectively indicated as red or blue tiles. Mutations present in every sequenced region from a given patient are portrayed by solid tiles, and mutations present in only a subset of tissues from a given patient are portrayed by faded tiles. Mutations are grouped into three categories based on their deduced order of emergence during progression: primary drivers (shared and fully clonal), secondary drivers (shared and usually clonal), and tertiary drivers (private to later stages and typically subclonal).](nihms-1529305-f0002){#F2}

![Mutations disrupting chromatin remodeling factors emerge throughout the progression to metastatic disease.\
**a--c,** Exemplary phylogenetic trees in which *BAP1* loss emerged early (**a**) and late (**b**,**c**). In cases with early loss, bi-allelic loss-of-function mutations reside on the trunks of the trees, whereas in cases where it arose later, at least one hit is situated on a branch. **d,** Dual immunostaining for BAP1 (brown) and melan-A (red) demonstrates that A13 and A29 metastases are null or BAP1 protein. **e,** Cases in which mutations in other chromatin remodeling factors were detected. These alterations tended to arise later, positioning them on the branches.](nihms-1529305-f0003){#F3}

![Gene dosage of chromosome 8q increases during progression.\
**a,** Examples of phylogenetic trees in which gains of 8q occur early and subsequently increase (see [Supplementary Figs. 1b](#SD1){ref-type="supplementary-material"} and [4](#SD1){ref-type="supplementary-material"} for more details on these copy number alterations). **b,** Examples of phylogenetic trees of tumors in which metastatic dissemination preceded gain of 8q. The detailed evolution of each case is available in the supplementary dataset (see [Methods](#S9){ref-type="sec"}). **c,** Copy number increase of 8q in metastases and primary tumors is shown on the *y*-axis, with 0 reflecting the normal, diploid state. Red bars denote averages, indicating that in our cohort the level of 8q copy number increase doubled from primaries to metastases (*P* = 0.002, two-tailed *t*-test).](nihms-1529305-f0004){#F4}

![The sequential order of genetic alterations during metastatic progression.\
**a,** Top panel: the *y*-axis indicates the relative fraction of patients in which the indicated somatic alterations occupied the trunk or branches of their respective phylogenetic trees. Somatic alterations that were more common in the trunks of phylogenetic trees were assumed to undergo selection earlier than those situated on their branches. Bottom panel: the number of patients with each of the indicated somatic alterations. **b,** Enrichment scores (*P*-values) were calculated using a two-tailed binomial test (see [Methods](#S9){ref-type="sec"} for details) for the 15 genetic alterations highlighted in **a** to determine whether they were more common in primary tumors (*n* = 53) or in metastases (*n* = 36). Vertical gray lines indicate *P*-values of 0.05. Scores were calculated under the assumption (null hypothesis) that somatic alterations are equally distributed between primaries and metastases. Most somatic alterations were enriched in metastases, though only 6q loss, gain of at least 3 copies of 8q, and gain of 1q reached statistical significance.](nihms-1529305-f0005){#F5}

![The evolution of metastatic uveal melanoma.\
'CNA', copy number alteration. 'Other CNAs' include combinations of 16q loss, 8p loss, 6q loss, or 6p gain, among others. 'Additional pathogenic mutations' include various combinations of 8q amplification, 1q gain, *CDKN2A* loss, SWI/SNF mutations, and *EZH2* mutations, among others. The precursors to primary uveal melanoma are not well understood, as reflected here by the questions marks adjacent to those clinical stages in our model.](nihms-1529305-f0006){#F6}
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